Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by alveolar epithelial cell injury and lung fibroblast overactivation. At present, only two drugs are approved by the FDA for the treatment of IPF, including the synthetic pyridinone drug,...
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
BMC
2023-03-01
|
| Serie: | BMC Pulmonary Medicine |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12890-023-02385-9 |